Hutchison China MediTech Ingresos Q/Q
¿Qué es el Ingresos Q/Q de Hutchison China MediTech?
El Ingresos Q/Q de Hutchison China MediTech Ltd. es -42.64%
¿Cuál es la definición de Ingresos Q/Q?
El crecimiento de los ingresos trimestrales, año tras año, es el aumento de los ingresos de una empresa en comparación con el compiortamiento en el trimestre correspondiente de un año anterior expresado como un porcentaje.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Ingresos Q/Q de compañías en Sector Health Care en LSE en comparadas con Hutchison China MediTech
¿Qué hace Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Empresas con ingresos q/q similar a Hutchison China MediTech
- Venzee Technologies tiene Ingresos Q/Q de -42.73%
- Stereotaxis tiene Ingresos Q/Q de -42.72%
- Riba Textiles tiene Ingresos Q/Q de -42.69%
- Bega Cheese tiene Ingresos Q/Q de -42.68%
- Nagreeka Exports tiene Ingresos Q/Q de -42.67%
- Bowl America tiene Ingresos Q/Q de -42.67%
- Hutchison China MediTech tiene Ingresos Q/Q de -42.64%
- Startek tiene Ingresos Q/Q de -42.61%
- Integrated Diagnostics plc tiene Ingresos Q/Q de -42.57%
- iSentric tiene Ingresos Q/Q de -42.50%
- Skyline tiene Ingresos Q/Q de -42.50%
- 51 Credit Card tiene Ingresos Q/Q de -42.44%
- Broo tiene Ingresos Q/Q de -42.42%